中国脑瘤发病和死亡流行现况及预测

doi:10.16352/j.issn.1001-6325.2024.04.0454

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (4): 454-458.doi: 10.16352/j.issn.1001-6325.2024.04.0454

中国脑瘤发病和死亡流行现况及预测

雷少元¹, 李玉龙², 孙菲³, 刘宏军¹, 吴月³, 郭艳苏^1,3,4*

1.首都医科大学宣武医院循证医学中心,北京 100053;
2.中共中央办公厅警卫局保健处,北京 100034;
3.首都医科大学宣武医院老年保健及疾病防治中心办公室,北京 100053;
4.北京市老年病医疗研究中心,北京 100053

收稿日期:2023-11-28 修回日期:2024-01-18 出版日期:2024-04-05 发布日期:2024-03-25
通讯作者: ^*gys188@163.com
基金资助:
国家自然科学基金(81971200);北京市自然科学基金(7222082);北京市老年病医疗研究中心改革与发展项目(11000023T000002036320)

The epidemiology and prediction of brain tumors incidence and mortality in China

LEI Shaoyuan¹, LI Yulong², SUN Fei³, LIU Hongjun¹, WU Yue³, GUO Yansu^1,3,4*

1. Department of Evidence-Based Medicine, Xuanwu Hospital, Capital Medical University, Beijing 100053;
2. Health Service Department of the Guard Bureau of the General Office of the Central Committee of the Communist Party of China, Beijing 100034;
3. Beijing Geriatric Healthcare Center, Xuanwu Hospital, Capital Medical University, Beijing 100053;
4. Beijing Municipal Geriatric Medical Research Center, Beijing 100053, China

Received:2023-11-28 Revised:2024-01-18 Online:2024-04-05 Published:2024-03-25
Contact: ^*gys188@163.com

摘要/Abstract

摘要： 目的描述2020年中国脑瘤发病和死亡的流行现况,预测到2040年中国脑瘤发病和死亡负担,为更科学的制定我国脑瘤防治策略提供数据支持。方法提取国际癌症研究署(IARC)2020年Cancer Today数据库。采用Segi's世界标准人口的年龄构成计算脑瘤的年龄标化发病率和死亡率。分性别、年龄别描述中国脑瘤发病和死亡情况。利用《世界人口展望(2022)》数据结合脑瘤发病和死亡率预测到2040年中国脑瘤发病和死亡负担。结果 2020年中国脑瘤新发病例约8.0万人,死亡约6.5万人,年龄标化发病率和死亡率分别为4.1/10万和3.2/10万。中国脑瘤的年龄标化发病率低于美国、绝大部分欧洲、北美洲等地区脑瘤发病率,但高于非洲、中美洲、加勒比海等地区。2040年中国脑瘤的发病和死亡人数相比2020年分别增长32.1%和41.5%。结论中国脑瘤负担整体比较严重,需进一步明确人群脑瘤危险因素,有针对性地完善相应防控策略以降低脑瘤负担。

关键词: 脑瘤, 发病率, 死亡率, 中国

Abstract: Objective To describe the incidence and mortality of brain tumors in China in 2020 and to predict the disease burden up to 2040. Methods The brain tumor incidence and mortality in 2020 were recorded based on the data from International Agency for Cancer Research(IARC), Cancer Today database. The incidence and mortality were standardized by age using Segi's world standard population. The burden of brain tumors in 2040 was predicted with assuming that national rates remained constant in 2020. Results It was estimated there were approximately 79 600 new brain tumors cases and 65 200 deaths in China in 2020. The age-standardized incidence and mortality rates of brain tumors in China were 4.1/100 000 and 3.2/100 000, respectively, which were lower than the United States of America, most of European countries and Australia. The incidence and mortality were higher than Africa, central America, and the Caribbean. From 2020 to 2040, the brain tumors cases and deaths are predicted to have an increase as 32.1% and 41.5% respectively. Conclusions The disease burden of brain tumors was still heavy in China. Further studies are urgently needed to clarify the epidemic trend of tissue typing and risk factors of brain tumors, which may support the development of effective prevention strategies.

Key words: brain tumors, incidence, mortality, China

中图分类号:

R739.4

雷少元, 李玉龙, 孙菲, 刘宏军, 吴月, 郭艳苏. 中国脑瘤发病和死亡流行现况及预测[J]. 基础医学与临床, 2024, 44(4): 454-458.

LEI Shaoyuan, LI Yulong, SUN Fei, LIU Hongjun, WU Yue, GUO Yansu. The epidemiology and prediction of brain tumors incidence and mortality in China[J]. Basic & Clinical Medicine, 2024, 44(4): 454-458.

参考文献 13

[1]	Zheng RS, Zhang SW, Zeng HM, et al. Cancer incidence and mortality in China, 2016[J]. JNCC, 2022, 2:1-9. doi: 10.1016/j.jncc.2022.02.002.
[2]	丛明华,宋晨鑫,郑荣寿,等. 2011年中国脑和神经系统肿瘤发病和死亡分析[J]. 中国肿瘤,2015,24:349-353. doi:10.11735/j.issn.1004-0242.2015.05.A001.
[3]	孟凡影,李国夫,于雷,等. 1990-2019年中国脑和中枢神经系统肿瘤疾病负担[J]. 国际流行病学传染病学杂志,2023, 50:153-158. doi:10.3760/cma.j.cn331340-20230127-00011.
[4]	Bray F, Ferlay J, Laversanne M, et al. Cancer incidence in five continents: inclusion criteria, highlights from volume X and the global status of cancer registration[J]. Int J Cancer, 2015,137: 2060-2071.doi: 10.1002/ijc.29670.
[5]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71:209-249. doi: 10.3322/caac.21660.
[6]	Bray F, Guilloux A, Sankila R, et al. Practical implications of imposing a new world standard population[J]. Cancer Causes Control, 2002, 13: 175-182. doi: 10.1023/a:1014344519276.
[7]	Ostrom QT, Francis SS, Barnholtz-Sloan JS. Epidemio-logy of brain and other CNS tumors[J].Curr Neurol Neurosci Rep, 2021, 21: 68. doi: 10.1007/s11910-021-01152-9.
[8]	韩仁强,周金意,张思维,等.2015年中国脑瘤发病与死亡分析[J].中国肿瘤, 2021,30:29-34. doi: 10.11735/j.issn.1004-0242.2021.01.A002.
[9]	Ostrom QT, Price M, Neff C, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019[J]. Neuro Oncol, 2022; 24(Suppl 5): v1-v95. doi: 10.1093/neuonc/noac202.
[10]	Sadetzki S, Chetrit A, Freedman L, et al. Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis[J]. Radiat Res, 2005, 163: 424-432. doi: 10.1667/rr3329.
[11]	Miranda-Filho A, Piñeros M, Soerjomataram I, et al. Cancers of the brain and CNS: global patterns and trends in incidence[J]. Neuro Oncol, 2017, 19: 270-280. doi: 10.1093/neuonc/now166.
[12]	Kang H, Song SW, Ha J, et al. A nationwide, population-based epidemiology study of primary central nervous system tumors in Korea, 2007—2016: a comparison with United States data[J]. Cancer Res Treat, 2021, 53: 355-366. doi: 10.4143/crt.2020.847.
[13]	Glied S, Jackson A. The future of the affordable care act and insurance coverage[J]. Am J Public Health, 2017, 107: 538-540. doi: 10.2105/ajph.2017.303665.

中国脑瘤发病和死亡流行现况及预测

The epidemiology and prediction of brain tumors incidence and mortality in China

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 13

相关文章 9

编辑推荐

Metrics

本文评价

[1]	孙爱华, 赵艳秋, 王继灵. 老年慢性阻塞性肺部疾病急性加重期患者住院死亡的危险因素及预后[J]. 基础医学与临床, 2022, 42(9): 1414-1418.
[2]	韩亮, 卓彦伶. 哥伦比亚大学玻璃体视网膜专科医师培训启示[J]. 基础医学与临床, 2022, 42(7): 1152-1155.
[3]	张翰林, 王乃利, 张迪, 刘润竹, 崔欢, 唐珂韵, 曹承刚, 马超. 中国遗体捐献的过去、现在与未来[J]. 基础医学与临床, 2021, 41(9): 1356-1359.
[4]	杨丹, 吴群励, 梁晓春, 田国庆, 孙华, 朴元林, 张孟仁. 北京协和医学院护理学院本科生2020年“中医学”线上课程的教学评价[J]. 基础医学与临床, 2021, 41(5): 772-775.
[5]	王轶, 曹戌, 马新春, 张英, 马艳艳. 文献报告会有助于中国西部地区医院的科学研究[J]. 基础医学与临床, 2021, 41(5): 776-778.
[6]	曹邓晗, 陈奎生. miR-197-3p调控DMBT1抑制甲状腺癌细胞系增殖、迁移和侵袭[J]. 基础医学与临床, 2020, 40(5): 644-650.
[7]	刘力. 新型冠状病毒SARS-CoV-2: 高致病性及其防治[J]. 基础医学与临床, 2020, 40(4): 433-439.
[8]	刘亚举龙飞李瑾岳俊涛石美森. 19个X-STR 基因座在中国3个民族的遗传学调查及法医学应用[J]. 基础医学与临床, 2018, 38(7): 913-921.
[9]	鲁瑾邹大进. 肥胖人群中瘦素受体基因Lys656Asn多态性与血三酰甘油水平的相关性[J]. 基础医学与临床, 2008, 28(3): 252-255.